Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4866—Organic macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4833—Encapsulating processes; Filling of capsules
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4858—Organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids

Definitions

• the present disclosure relates to an oral immediate release, abuse deterrent dosage form.
• the dosage form contains polyethylene glycol (PEG) to reduce abuse by non-oral administration routes, e.g. intranasal and/or intravenous.
• PEG polyethylene glycol
• the composition of PEG is designed to allow for immediate release of the active ingredient while deterring abuse and maintaining stability of the dosage form at elevated temperatures.
• FDA-approved drugs are provided in many different forms based on the type of active substance, the indication treated and the preferred route of administration. These forms include enteral formulations (e.g., tablets, capsules or pills), parenteral formulations (e.g., injectable formulations such as intravenous, subcutaneous, intramuscular and intraarticular), liquid formulations (e.g., elixirs), lyophilized formulations and topical formulations.
• enteral formulations e.g., tablets, capsules or pills
• parenteral formulations e.g., injectable formulations such as intravenous, subcutaneous, intramuscular and intraarticular
• liquid formulations e.g., elixirs
• lyophilized formulations e.g., lyophilized formulations and topical formulations.
• a majority of the FDA-approved drugs are currently available in enteral form, as either a tablet or capsule.
• U.S. 2014/0010873 (assigned to Egalet Ltd.) is directed to an abuse-deterrent pharmaceutical composition including at least one polyethylene oxide and at least one plasticizer.
• the polyethylene oxide has an average molecular weight of at least 1 ,000,000 Daltons, and the pharmaceutical composition includes at least 5 percent w/w of the at least one plasticizer.
• the pharmaceutical composition is designed to prevent immediate release of the at least one active drug substance after physical tampering.
• 2009/0123386 (assigned to MW Encap Limited) is directed to an abuse deterrent capsule including at least one modifier selected to prevent abuse.
• the modifier may have a high melting point or be insoluble in aqueous solvents or ethanol.
• the high melting point excipient may be Poloxamer 188 or PEG 8000.
• U.S. 2010/0204259 (assigned to Egalet A/S) is directed to immediate release pharmaceutical compositions that are resistant to abuse by intake of alcohol. The release of the drug substance from the immediate release composition is decreased when the composition is exposed to a dissolution medium that includes ethanol.
• the compositions may be formulated to include at least one polyglycol and at least one effervescent agent.
• the present disclosure relates to an immediate release, abuse deterrent capsule including an active substance susceptible to abuse, a first polyethylene glycol (PEG) having an average molecular weight between about 30,000 Daltons and about 40,000 Daltons; and a second PEG having an average molecular weight between about 3000 Daltons and about 4000 Daltons.
• the ratio of the first PEG to the second PEG is less than about 1 :4 w/w.
• the first PEG and the second PEG together are at least about 60 wt% of the dosage form.
• the active substance is hydrocodone bitartrate.
• the active substance is oxycodone hydrochloride (HC1).
• the capsule includes a grey dye including FD&C Blue #1 , FD&C Yellow #6, and FD&C Red #40.
• the dye reduces abuse by providing a visual deterrent to injecting.
• about 60%, 70% 75%, 80%, 85% or about 90% or more of the capsule fill contents are soluble in both water and/or alcohol, e.g., ethanol.
• the ratio of the first PEG to the second PEG is between about 1 :7 w/w and about 1 : 1 1 w/w.
• the first PEG has an average molecular weight of about 35,000 Daltons and the second PEG has an average molecular weight of about 3350 Daltons.
• the capsule includes at least about 2.5 wt% of the active substance.
• the capsule may be prepared by filling a capsule body with a heated homogenized suspension including the active substance, the first PEG and the second PEG.
• the present disclosure also relates to an immediate release, abuse deterrent capsule including an active substance susceptible to abuse and polyethylene glycol with a weighted average molecular weight between about 6200 Daltons and about 7800 Daltons.
• the capsule includes at least about 60 wt% of PEG.
• the active substance is hydrocodone bitartrate.
• the active substance is oxycodone HC1.
• the present disclosure also relates to an immediate release, abuse deterrent capsule including an active substance susceptible to abuse, a first PEG having a melting point greater than or equal to about 60 °C, and a second PEG having a melting point less than or equal to about 57 °C.
• the contents of the capsule can be solid at 40 °C / 75% relative humidity.
• at least 90% of the active ingredient can be released from the capsule within 30 minutes following administration or via dissolution testing.
• at least 75% of the active ingredients can be released from the capsule within 45 minutes following administration or via dissolution testing.
• the first PEG and the second PEG together are at least about 60 wt% of the capsule.
• the active substance is hydrocodone bitartrate.
• the active substance is oxycodone HC1.
• the present disclosure also relates to a process for the production of an immediate release, abuse deterrent capsule including at least one active substance susceptible to abuse including preparing a homogenized suspension of the at least one active substance susceptible to abuse, a first PEG having an average molecular weight between about 30,000 Daltons and about 40,000 Daltons, and a second PEG having an average molecular weight between about 3000 Daltons and about 4000 Daltons.
• the process can further include filling the homogenized suspension into a capsule body to produce an encapsulated dosage form.
• the ratio of the first PEG to the second PEG can be less than about 1 :4 w/w, e.g., between about 1 :7 w/w and about 1 : 1 1 w/w.
• the first PEG and the second PEG together can be at least about 60 wt% of the capsule.
• the active substance is hydrocodone bitartrate.
• the active substance is oxycodone HC1.
• the capsule can be formed by joining a capsule body with a capsule cap.
• the present disclosure also relates to a method of treating pain including
• Figure 1 shows cross sections of a capsule filling machine including the body segment, the cap disc, the hopper, the pumping box, the substation roller, and capsule bodies.
• Figure 2A shows solutions of grey dye before filtering.
• Figure 2B shows solutions of grey dye after filtering.
• Figure 3 shows a summary of an exemplary manufacturing process for formulations of the present disclosure.
• Figure 4 shows unfiltered solutions of the dosage forms in 190 proof ethanol after shaking at 250 rpm for 3 hours.
• Figure 5 shows syringe-filtered solutions of the dosage forms in 190 proof ethanol after shaking at 250 rpm for 3 hours.
• agonist/antagonist combinations aversion, delivery system, prodrug, or a combination of the aforementioned.
• the categories are: [0020] Physical/Chemical barriers - Physical barriers can prevent chewing, pulverizing, cutting, grating, or grinding. Chemical barriers can resist extraction of the opioid using common solvents like water, alcohol, or other organic solvents. Physical and chemical barriers can change the physical form of an oral drug rendering it less amenable to abuse.
• An opioid antagonist can be added to interfere with, reduce, or defeat the euphoria associated with abuse.
• the antagonist can be sequestered and released only upon manipulation of the product.
• a drug product may be formulated such that the substance that acts as an antagonist is not clinically active when the product is swallowed but becomes active if the product is crushed and injected or snorted.
• Aversion - Substances can be combined to produce an unpleasant effect if the dosage form is manipulated prior to ingestion or a higher dosage than directed is used.
• Delivery System including depot injectable formulations and implants
• Certain drug release designs or the method of drug delivery can offer resistance to abuse.
• a sustained-release depot injectable formulation that is administered intramuscularly or a subcutaneous implant can be more difficult to manipulate.
• Prodrug - A prodrug that lacks opioid activity until transformed in the gastrointestinal tract can be unattractive for intravenous injection or intranasal routes of abuse.
• Combination - Two or more of the above methods can be combined to deter abuse.
• An opioid analgesic submitted for abuse deterrent formulation (ADF) labeling must show conformance to one or more of these categories.
• the present disclosure relates to an abuse deterrent dosage form for oral administration, which provides immediate release of an active pharmaceutical substance and conforms to one or more of these categories.
• the abuse deterrent dosage form of the present disclosure conforms to at least one of the six FDA categories.
• the abuse deterrent dosage form of the present disclosure conforms to at least two of the six FDA categories.
• the abuse deterrent dosage form of the present disclosure conforms to at least three of the six FDA categories.
• the abuse deterrent dosage form of the present disclosure conforms to at least four of the six FDA categories.
• an abuse deterrent dosage form of the present disclosure conforms to at least five of the six FDA categories.
• an abuse deterrent dosage form of the present disclosure can reduce abuse by the incorporation of at least one physical barrier.
• the physical barrier is designed to prevent abuse based on chewing, pulverizing, cutting, grating or grinding.
• the physical barrier prevents or reduces the effectiveness of these methods.
• the phrase "abuse deterrent" means that the active substance cannot readily be separated from the formulation in a form suitable for abuse by such means as, for example, grinding.
• the abuse deterrent form of the present disclosure cannot be easily ground, extracted from, or both. Abuse deterrent measures render it difficult to transform the dosage form into a residue or extract for non-oral administration, such as intranasal or intravenous.
• the present disclosure relates to an oral, immediate release, abuse deterrent dosage form including an active substance susceptible to abuse, a first PEG having an average molecular weight between about 30,000 Daltons and about 40,000 Daltons, and a second PEG having an average molecular weight between about 3000 Daltons and about 4000 Daltons.
• the ratio of the first PEG to the second PEG can be less than about 1 :4 w/w.
• the wt% of active substance in the formulation may also vary depending on the active substance of the dosage form.
• the dosage form includes at least about 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, 1.0 wt%, 1.1 wt%, 1.2 wt%, 1 .3 wt%, 1.4 wt%, 1.5 wt %, 2 wt%, 2.5 wt%, 3 wt%, 4 wt%, 5 wt%, 6 wt%, 7 wt%, 7.5 wt%, 8 wt%, 9 wt%, 10 wt%, 1 1 wt%, 12 wt%, 13 wt%, 14 wt%, 15 wt%, 16 wt%, 17 wt%, 18 wt%, 19 wt%, 20 wt%, 21 wt%, 22 .
• the amount of active substance in the dosage form may range from about 0.10 wt% to about 60 wt%.
• the amount of active substance in the dosage form may range from about 0.1 wt% to about 1.5 wt%, from about 5 wt% to about 30 wt%, from about 15 wt% to about 20 wt%, from about 15 wt% to about 30 wt%, from about 40 wt% to about 60 wt%, from about 40 wt% to about 50 wt%, or from about 42 wt% to about 46 wt%.
• the dosage form may be a 100 mg capsule including about 5 mg, about 10 mg, about 15 mg, about 20 mg, or about 30 mg of active substance (e.g., oxycodone HC1).
• the dosage form may be a 150 mg capsule including about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 30 mg, or about 45 mg of active substance (e.g., oxycodone HC1).
• the dosage form may be a 200 mg capsule including about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, or about 60 mg of active substance (e.g., oxycodone HC1).
• the dosage form may be a 700 mg capsule including about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 15 mg, about 20 mg, about 30 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg or about 100 mg of an active substance (e.g., hydrocodone bitartrate).
• an active substance e.g., hydrocodone bitartrate
• the term "active” or “active substance” or “active substance susceptible to abuse” or “API” means any opioid or opioid related compound subject to potential abuse.
• the active substance may include, without limitation, alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone
• phenadoxone phenazocine
• phenomorphan phenoperidine
• piminodine propiram
• the active can be oxycodone HC1 or hydrocodone bitartrate.
• the active substance is not oxymorphone.
• the active substance can be hydrocodone bitartrate or oxycodone HC1.
• the dosage form of the present disclosure can be rendered abuse deterrent by incorporating PEG in the dosage form.
• the PEG can deter abuse by preventing at least 50%, or at least 75%, of the capsule weight from being ground to a particle size below 500 ⁇ m, such as after 30 seconds of milling at 10,000 RPM.
• PEG can also prevent extraction of the active substance from the dosage form using an alcohol.
• Abusers can use the partial solubility characteristics of dosage form excipients to extract the active substance using alcohol and subsequently burn off the alcohol to form a purer residue containing the active substance.
• PEG poly(ethylene glycol)
• Addition of a dye to the dosage form can also result in a colored solution after extraction of the active substance, deterring intravenous injection.
• PEG in the dosage form can result in the inability of the dosage form, e.g., capsule, to be abused by pulverizing and snorting, pulverizing and injecting, or
• the abuse deterrent dosage form of the present disclosure may be incapable of being significantly pulverized by physical or mechanical force due at least in part to the waxy characteristics of the PEG.
• One of the most common means of abuse of an orally administered opioid analgesic involves the manipulation of the oral dosage form in order to cause rapid delivery to the bloodstream via nasal insufflation.
• the original dosage form In order for insufflation to be used as an effective means of abuse, the original dosage form must be manipulated so as to decrease the particle size of the ingested drug to about 500 ⁇ m or less.
• a particle size of about 500 ⁇ m or less is necessary for effective intranasal absorption to occur.
• one way to prevent abuse by nasal insufflation is by capturing the active substance susceptible to abuse in a matrix which is resistant to being physically broken down to produce particles smaller than about 500 ⁇ m.
• the dosage form of the present disclosure can inhibit manipulation by grinding or pulverizing using common equipment, such as a coffee grinder.
• the formulation can deter abuse by limiting the particle size to which the formulation may be ground.
• the formulation prevents the dosage form, or at least substantial portions of the dosage from, from being ground in particles having a particle size of about 500 ⁇ m or less that may pass through the mucus membranes of the nasal cavity.
• the dosage form can also significantly limit the extraction of the active substance by common solvents (e.g., cold water or distilled aqueous ethanol) from the formulation.
• the formulation deters abuse by limiting the ability of persons to extract the active substance from the formulation (either intentionally or unintentionally), such that the active substance cannot easily be concentrated for parenteral administration.
• the abuse deterrent dosage form may also include, but does not require, the incorporation of other deterrents such as antagonists or irritants.
• the abuse deterrent can work as follows. If the dosage form is extracted with alcohol or an aqueous solution, the PEG and/or dye will also be extracted and cannot easily be separated from the active substance, preventing the preparation of pure drug for intravenous administration. Extraction with a solution would result in a grey/black liquid containing the PEG, dye and active substance.
• the inclusion of PEG in the formulation can prevent or reduce extraction because PEG can melt and form a wax before the alcohol can be completely evaporated or flashed off, an abuser may not be able to obtain a residue containing the active substance.
• These properties can allow for an oral drug delivery system that satisfies at least one of the categories in the FDA guidance (e.g., "physical and chemical barriers can change the physical form of an oral drug rendering it less amenable to abuse").
• the PEG can be capable of allowing immediate release of the active substance, providing abuse deterrence, and/or ensuring the formation of a solid dosage form that is stable at elevated temperatures, for example 40 °C.
• the PEG provides all three.
• the dosage form of the present disclosure can accomplish the above capabilities by using a mixture of PEG molecules of at least two different average molecular weights.
• the dosage form may include a first PEG having an average molecular weight between about 30,000 Daltons and 40,000 Daltons, and a second PEG having an average molecular weight about 3000 Daltons and 4000 Daltons.
• the first PEG has an average molecular weight of about 20, 000, 21 ,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000, 30,000, 30,500, 31 ,000, 31 ,500, 32,000, 32,500, 33,000, 33,500, 34,000, 34,500, 35,000, 35,500, 36,000, 36,500, 37,000, 37,500, 38,000, 38,500, 39,000, 39,500 or 40,000 Daltons. Any of these values may be used to define a range for the average molecular weight of the first PEG.
• the first PEG can have an average molecular weight between about 31 ,000 Daltons and about 39,000 Daltons, between about 32,000 Daltons and about 38,000 Daltons, between about 33,000 Daltons and about 37,000 Daltons, between about 34,000 Daltons and about 36,000 Daltons, between about 30,000 Daltons and about 32,000 Daltons, between about 32,000 Daltons and about 34,000 Daltons, between about 36,000 Daltons and about 38,000 Daltons, or between about 38,000 Daltons and about 40,000 Daltons.
• the second PEG can have an average molecular weight of 3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950 or 4000 Daltons. Any of these values may be used to define a range for the average molecular weight of the second PEG.
• the second PEG can have an average molecular weight between about 3100 Daltons and about 3900 Daltons, between about 3200 Daltons and about 3800 Daltons, between about 3300 Daltons and about 3700 Daltons, between about 3400 Daltons and about 3600 Daltons, between about 3000 Daltons and 3200 Daltons, between about 3200 Daltons and about 3400 Daltons, between about 3600 Daltons and about 3800 Daltons, or between about 3800 Daltons and about 4000 Daltons.
• the ratio of the first PEG to the second PEG can be about 3:1, 2:1, 1:1, 1:2, 1:3.1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1 : 19 or 1 :20. Any of these values may be used to define a range for the ratio of the first PEG to the second PEG.
• the ratio of the first PEG to the second PEG can be between about 1 :2 w/w and about 2:1 w/w, between about 1 :3 w/w and about 1:1 w/w, between about 1 :2 w/w and about 1 : 1 w/w, between about 1 : 1 w/w and about 2: 1 w/w, between about 1 : 1 w/w and about 3 : 1 w/w, between about 1 :4 w/w and about 1:10 w/w, between about 1 :7 w/w/ and about 1:11 w/w, or between about 1 :8 w/w and about 1:10 w/w.
• the ratio of the first PEG to the second PEG can be less than about 3:1,2:1, 1:1, 1:2, 1:3.1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, l:19or 1 :20.
• a ratio of 1 :10 is less than a ratio of 1 :9.
• the total wt% of PEG in the dosage form may vary depending on the active substance, stability, and release profile.
• the first PEG and the second PEG together are at least about 5 wt%, 10 wt%, 15 wt%, 20 wt%, 25 wt%, 30 wt%, 35 wt%, 36 wt%, 37 wt%, 38 wt%, 39 wt%, 40 wt%, 41 wt%, 42 wt%, 43 wt%, 44 wt%, 45 wt%, 46 wt%, 47 wt%, 48 wt%, 49 wt%, 50 wt%, 51 wt%, 52 wt%, 53 wt%, 54 wt%, 55 wt%, 56 wt%, 57 wt%, 58 wt%, 59 wt%, 60 wt%, 61 wt%, 62
• the formulation includes a disintegrant.
• a disintegrant promotes disintegration of the capsule, and dissolution of the active substance, after administration and upon contact with water.
• the disintegrant may be selected from sodium starch glycolate, cross- linked polyvinylpyrrolidone (e.g. crospovidone), cross-linked sodium carboxymethylcellulose (e.g. croscarmellose sodium) sodium bicarbonate/citric acid, alginic acid or combinations thereof.
• the disintegrant is selected from sodium starch glycolate, crospovidone and croscarmellose.
• the dosage form may contain about 1 wt%, 2 wt%, 3 wt%, 4 wt%, 5 wt%, 6 wt%, 7 wt%, 8 wt%, 9 wt%, 10 wt%, 1 1 wt%, 12 wt%, 13 wt%, 14 wt%, 15 wt%, 16 wt%, 17 wt%, 18 wt%, 19 wt% or 20 wt% of disintegrant. Any of these values may be used to define a range for the wt% of disintegrant.
• the dosage form may contain between about 1.0 wt% and about 20 wt% of disintegrant.
• the formulation may contain between about 1.0 wt% and about 10 wt% disintegrant or between about 5 wt% and about 8 wt% disintegrant.
• the dosage form includes 5 wt% sodium starch glycolate, 8 wt% sodium starch glycolate, 5 wt% crospovidone, or 5 wt% croscarmellose sodium.
• the dosage form of the present disclosure excludes a
• the formulation includes a dye.
• a dye can be useful in deterring abuse by discouraging the abuser from intravenous injection. For example, extraction of the dye along with the active ingredient would result in a colored solution that would discourage the abuser from intravenous injection. Thus, in certain embodiments, the dye reduces abuse by extracting and injecting.
• the dye may be selected from known dyes suitable for use in pharmaceutical formulations or approved by the FDA for such use. For example, the dye may be FD&C Blue No. 2 or a 50/50 wt% solution of FD&C Blue No. 2 in PEG. In another
• the dye may be a grey dye including FD&C Blue #1 , FD&C Yellow #6, and FD&C Red #40.
• the dye may be in a 90% PEG 3350 blend.
• 14 mg of dye blend can be used in each capsule or about 1.4 mg of concentrated dye.
• a grey dye is used since it is visually deterring and non-transparent.
• the dosage form may include about 0.10 wt%, 0.20 wt%, 0.30 wt%, 0.40 wt%, 0.50 wt%, 1 wt%, 2 wt%, 3 wt%, 4 wt%, 5 wt%, 6 wt%, 7 wt%, 8 wt%, 9 wt%, 10 wt%, 1 1 wt%, 12 wt%, 13 wt%, 14 wt%, 15 wt%, 16 wt%, 17 wt%, 18 wt%, 19 wt%, or 20 wt% dye. Any of these values may be used to define a range for the wt% of the dye.
• the dosage form may contain between about 0.10 wt% and about 15 wt% dye.
• the dosage form may contain between about 0.20 wt% and about 1.5 wt% dye, about 0.50 wt% and about 1.0 wt% dye , or about 7 to about 14 wt% dye.
• the dosage form may include about 1 mg, 1.4 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 nig, 10 mg, 1 1 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg or 30 mg of dye.
• the dosage form of the present disclosure excludes a dye.
• the dosage form includes a first dye and a second dye, wherein the first dye has a high solubility in aqueous solution that is higher than the solubility of the second dye in aqueous solution.
• the first dye has a solubility in aqueous solution of about 1 g, 5 g, 10 g, 30 g, 50 g, 100 g or 500 g in 1 L of aqueous solution and the second dye has a solubility in aqueous solution of about 1 mg, 5 mg, 10 mg, 30 mg, 50 mg, 100 mg, 500 mg, 1 g, or 10 g in 1 L of aqueous solution.
• the second dye has a high solubility in non-aqueous solution that is greater than the solubility of the first dye in non-aqueous solution.
• the first dye has a solubility in non-aqueous solution of about 1 mg, 5 mg, 10 mg, 30 mg, 50 mg, 100 mg, 500 mg, 1 g, or 10 g in 1 L of non-aqueous solution
• the second dye has a solubility in non-aqueous solution of about 1 g, 5 g, 10 g, 30 g, 50 g, 100 g or 500 g in 1 L of non-aqueous solution.
• the color of the first dye is substantially the same as the color of the second dye.
• the color of the first dye is substantially different from the color of the second dye.
• a dye is considered to be soluble in a solvent if about 1 g of the dye can be dissolved in about 10-30 mL of the solvent.
• a dye is considered to be water soluble if about 1 g of the dye can be dissolved in 10-30 mL of water.
• the dosage form includes a preservative or antioxidant. The preservative or antioxidant can reduce or limit the degradation or deterioration of the abuse deterrent dosage form.
• the components of the oral drug delivery system may undergo degradation (e.g., oxidative reduction, chain cleavage) due to oxidation.
• Preventing degradation can help maintain the abuse deterrent properties of the formulation.
• the molecular weight of PEG in the formulation affects the resistance to grinding, for example, with a coffee grinder.
• the addition of a preservative or antioxidant in the formulation that reduces or eliminates the degradation of the molecular weight of PEG may be useful in maintaining the abuse deterrence properties of the dosage form.
• the addition of a preservative or antioxidant in the dosage form may be necessary to prevent premature degradation of the active substance over the shelf life of the dosage form.
• the preservative or antioxidant may be selected from preservatives or antioxidants known to one skilled in the art for use in pharmaceutical formulations, such as citric acid, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), erythorbic acid, hypophosphorous acid, lactobionic acid, monothioglycerol, potassium metabisulfite, propyl gallate, racemethionine, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium sulfite, sodium thiosulfate, stannous chloride, sulfur dioxide and tocopherols.
• preservatives or antioxidants known to one skilled in the art for use in pharmaceutical formulations, such as citric acid, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), erythorbic acid, hypo
• the formulation, or dosage form may contain between about 0.1 wt% and about 2.0 wt%, or about 0.25 wt% and about 0.75 wt% of preservative or antioxidant.
• the dosage form of the present disclosure excludes a preservative or antioxidant.
• the dosage form includes one or more excipients that form a gel in the presence of an alcohol.
• the alcohol gelling/thickening agent reduces or limits the potential for abuse by preventing extraction of the active substance from the dosage form.
• the components of the dosage form e.g., active substances, PEG
• the alcohol gelling/thickening agent does not form a gel in the presence of water.
• the dosage form can contain up to about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1 1%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39% or about 40%.
• These values can be used to define a range, such as about 0.1 wt% to about 40 wt% alcoholic gelling/thickening agent.
• the dosage form of the present disclosure does not contain an alcohol gelling/thickening agent.
• the alcohol gelling/thickening agent may be a gelling or thickening agent known to one skilled in the art for use in pharmaceutical formulations, such as acacia, alginic acid, bentonite, calcium acetate, carbomers, carboxymethylcellulose, ethylcellulose, gelatin, hydroxyethylcellulose, hydroxypropyl cellulose, magnesium aluminum silicate, methylcellulose, poloxamers, polyvinyl alcohol, polyvinyl acetate, polyvinylpyrrolidone, sodium alginate, sorbitol derivatives, tragacanth, or xanthan gum.
• acacia alginic acid
• bentonite calcium acetate
• carbomers carboxymethylcellulose
• ethylcellulose gelatin
• hydroxyethylcellulose hydroxypropyl cellulose
• magnesium aluminum silicate magnesium aluminum silicate
• methylcellulose poloxamers
• polyvinyl alcohol polyvinyl acetate, polyvinylpyrrolidon
• the dosage form may additionally include at least one additive independently selected from surfactants, bulking agents, lubricants, flavorings or combination thereof.
• the abuse deterrent dosage form of the present disclosure is capable of immediate release of the active substance.
• the dosage form may be manufactured to provide a composition exhibiting an immediate release profile of at least one active substance.
• immediate release refers to a dosage form that releases the active substance or a
• the amount of active substance released from the dosage form, e.g., oxycodone HC1 or hydrocodone bitartrate, by exposure to deaerated water within 45 minutes is greater than or equal to 75%.
• the amount of active substance released from the dosage form, e.g., hydrocodone bitartrate, by exposure to a 0.1 N hydrochloric acid solution within 30 minutes is greater than or equal to 90%.
• the amount of active substance released from the dosage form, e.g., oxycodone HC1, within 45 minutes is greater than or equal to 75%.
• the dosage form of the present disclosure releases greater than or equal to about 75% of the active substance within 45 minutes after administration or via dissolution testing. Particularly, the dosage form releases greater than or equal to about 80%, about 85%, about 90%, or about 95% of the active substance within 45 minutes after administration or via dissolution testing.
• the dosage form of the present disclosure releases greater than or equal to about 90% of the active substance within 30 minutes after administration or via dissolution testing. Particularly, the dosage form releases greater than or equal to about 92%, about 94%, about 96%, or about 98% of the active substance within 30 minutes after
• the present disclosure also relates to an oral, immediate release, abuse deterrent dosage form including an active substance susceptible to abuse and PEG with a weighted average molecular weight between about 6200 Daltons and about 7800 Daltons.
• dosage forms containing an average molecular weight of PEG in this particular range have several desirable characteristics including immediate release of the active substance, stability at high temperature conditions (e.g., 40 °C with 75% relative humidity), relatively low viscosity at elevated temperatures (e.g., a viscosity less than or equal to 2000 cP at 75 °C), and/or a relatively high particle size after grinding (e.g., greater than or equal to 50% of the particles having a diameter greater than or equal to 500 ⁇ m after grinding, such as for 30 seconds at 10,000 RPM).
• Dosage forms including PEG with an average molecular weight between about 6200 Daltons and about 7800 Daltons may be prepared by combining two or more PEGs with different molecular weights.
• any of the PEGs described herein e.g., PEG 3350 and PEG 35000
• PEG 3350 and PEG 35000 may be combined to prepare a dosage form including PEG with an average molecular weight range between about 6200 Daltons and about 7800 Daltons.
• the dosage form includes PEG, or two or more PEGs, with an average molecular weight of about 5000, 5015, 5100, 5200, 5300, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6515, 6600, 6700, 6800, 6900, 7000, 7100, 7200, 7300, 7400, 7500, 7600, 7700, 7800, 7900, 8000, 8100, 8200, 8300, 8400, 8500, 8600, 8700, 8800, 8900, 9000, 9100, 9200, 9300, 9400, 9500, 9600, 9700, 9800, 9900, 10,000, 10,100, 10,200, 10,300, 10,400, 10,500, 10,600, 10,700, 10,800, 10,900, 1 1 ,000, 1 1 ,100, 1 1,200, 1 1 ,300, 1 1 ,400, 1 1 ,500, 1 1 1 1 ,000, 1 ,
• the dosage form includes PEG, or PEGs, with an average molecular weight between about 6200 Daltons and about 6515 Daltons, between about 6515 Daltons and about 6800 Daltons, or between about 6200 Daltons and about 6800 Daltons.
• the present disclosure relates to an oral, immediate release, abuse deterrent dosage form including an active substance susceptible to abuse, a first PEG having a melting point greater than or equal to about 60 °C, and a second PEG having a melting point less than or equal to about 57 °C.
• the dosage form can be a solid at 40 °C / 75% relative humidity, and at least 90% of the active ingredient can be released from the dosage form within 30 minutes following administration or via dissolution testing.
• the dosage form can be a solid at 40 °C / 75% relative humidity, and at least 75% of the active ingredient can be released from the dosage form within 45 minutes following administration or via dissolution testing.
• the melting point of PEG can be positively con-elated with molecular weight, i.e. higher molecular weight PEGs have higher melting points.
• PEGs with an average molecular weight up to 400 Daltons can be considered nonvolatile liquids at room temperature.
• PEG 600 for example, has a melting range of about 17 to 22 °C, and may be liquid at room temperature but waxy at lower temperatures.
• PEGs with an average molecular weight of 800 to 2000 Daltons can be considered waxy materials at room temperature with a relatively low melting range.
• PEG 1500 has a melting point of about 42-46 °C.
• PEGs with an average molecular weight above 3000 can be considered solids.
• PEG 3350 has a melting point of about 53-57 °C
• PEG 35,000 has a melting point of about 60-65 °C.
• a dosage form with several desirable properties can be formed, including immediate release of an active substance, stability at high temperatures (e.g., 40° C with 75% relative humidity), relatively low viscosity at elevated temperatures (e.g., less than or equal to 2000 cP at 75 °C), and/or a relatively high particle size after grinding (e.g., greater than or equal to 50% of the particles having a diameter greater than or equal to 500 ⁇ m) and/or the incorporation of a chemical barrier which makes it difficult to separate the active substance from the rest of the formulation.
• stability at high temperatures e.g., 40° C with 75% relative humidity
• relatively low viscosity at elevated temperatures e.g., less than or equal to 2000 cP at 75 °C
• a relatively high particle size after grinding e.g., greater than or equal to 50% of the particles having a
• the dosage form includes a first PEG having a melting temperature greater than or equal to about 52 °C, 53 °C, 54 °C, 55 °C, 56 °C, 57 °C, 58 °C, 59 °C, 60 °C, 61 °C, 62 °C, 63 °C, 64 °C, 65 °C, 66 °C, 67 °C, 68 °C, 69 °C, or 70 °C. Any of these values may be used to define a range of melting temperatures for the first PEG depending on the application.
• the dosage form may include a first PEG having a melting
• the dosage form includes a second PEG having a melting temperature less than or equal to about 5 °C, 10 °C, 15 °C, 16 °C, 17 °C, 18 °C, 19 °C, 20 °C, 21 °C, 22 °C, 23 °C, 24 °C, 25 °C, 25 °C, 27 °C, 28 °C, 29 °C, 30 °C, 31 °C, 32 °C, 33 °C, 34 °C, 35 °C, 36 °C, 37 °C, 38 °C, 39 °C, 40 °C, 41 °C, 42 °C, 43 °C, 44 °C, 45 °C, 46 °C, 47 °C, 48 °C, 49 °C, 50 °C, 51 °C, 52 °C, 53 °C, 54 °C, 55 °C, 55 °C, 56 °C, or
• the dosage form may include a second PEG having a melting temperature between about 17 °C and about 22 °C, between about 42 °C and about 46 °C, between about 53 °C and about 57 °C, or between about 42 °C and about 57 °C.
• the dosage form includes a first PEG and a second PEG, wherein the first PEG and the second PEG combined have a melting temperature of about 42 °C, 43 °C, 44 °C, 45 °C, 46 °C, 47 °C, 48 °C, 49 °C, 50 °C, 51 °C, 52 °C, 53 °C, 54 °C, 55 °C, 56 °C, 57 °C, 58 °C, 59 °C, 60 °C, 61 °C, 62 °C, 63 °C, 64 °C, 65 °C, 66 °C, 67 °C, 68 °C, 69 °C, 70 °C. Any of these values may be used to define a range of melting temperatures for the combined first and second PEG depending on the application.
• the first PEG and the second PEG combined may have a melting temperature between about 53 °C and about 65
• the present disclosure relates to an oral, immediate release, abuse deterrent dosage form including an active substance susceptible to abuse, a first PEG having a melting point greater than or equal to about 60 °C and a second PEG having a viscosity at 100 °C less than or equal to about 1 10 cSt.
• the dosage form can be a solid at 40 °C / 75% relative humidity, and at least 75% of the active ingredient can be released from the dosage form within 45 minutes following administration or via dissolution testing or at least 90% of the active ingredient can be released from the dosage form within 30 minutes following administration or via dissolution testing.
• the dosage form includes a second PEG having a viscosity at 100 °C of less than or equal to about 500 cSt, 450 cSt, 400 cSt, 350 cSt, 300 cSt, 250 cSt, 200 cSt, 190 cSt, 180 cSt, 170 cSt, 160 cSt, 158 cSt, 150 cSt, 140 cSt, 130 cSt, 123 cSt, 120 cSt, 1 10 cSt, 105 cSt, 100 cSt, 99 cSt, 93 cSt, 90 cSt, 87 cSt, 80 cSt, 76 cSt, 75 cSt, 73 cSt, 70 cSt, 67 cSt, 60 cSt, 50 cSt, 49 cSt, 48 cSt, 47
• the dosage form may include a second PEG having a viscosity between about 4.0 cSt and about 49.0 cSt, between about 16.0 cSt and about 49.0 cSt, between about 25.0 cSt and about 32.0 cSt, or between about 76 cSt and about 1 10 cSt.
• the formulation of the present disclosure can have a viscosity at 100 °C of about 40 cSt, 41 cSt, 42 cSt, 43 cSt, 44 cSt, 45 cSt, 46 cSt, 47 cSt, 48 cSt, 49 cSt, 50 cSt, 51 cSt, 52 cSt, 53 cSt, 54 cSt, 55 cSt, 56 cSt, 57 cSt, 58 cSt, 59 cSt, 60 cSt, 61 cSt, 62 cSt, 63 cSt, 64 cSt, 65 cSt, 66 cSt, 67 cSt, 68 cSt, 69 cSt, 70 cSt, 71 cSt, 72 cSt, 73 cSt, 74 cSt, 75
• the formulation of the present disclosure may have a viscosity between about 500 cSt and about 2000 cSt, or between about 800 cSt and about 1900 cSt.
• the formulation or dosage form is a solid at room temperature and/or at 100 °C and has not measureable viscosity.
• the present disclosure relates to a process for the production of an oral, immediate release, abuse deterrent dosage form including preparing a homogenized suspension of at least one active substance susceptible to abuse, a first PEG, and a second PEG.
• the first PEG can have an average molecular weight between about 30,000 Daltons and about 40,000 Daltons
• the second PEG can have an average molecular weight between about 3000 Daltons and about 4000 Daltons.
• the ratio of the first PEG to the second PEG can be less than about 1 :4 w/w.
• the process can further include dispensing or filling a homogenized suspension into a capsule to produce the dosage form.
• the capsule can be formed by joining a capsule body with a capsule cap.
• the first PEG and the second PEG together may be any wt% of the dosage form as described herein, for example at least about 60 wt% of the dosage form.
• the active substance is hydrocodone bitartrate.
• the active substance is oxycodone HC1.
• the abuse deterrent dosage forms of the present disclosure are capsules.
• the abuse deterrent dosage forms of the present disclosure may be produced by liquid filled encapsulation.
• Liquid filled encapsulation is a process in which active pharmaceutical ingredients are suspended or emulsified in a carrier matrix and filled into capsules.
• the capsules are usually made of hard gelatin or hydroxypropyl methylcellulose.
• the internal solid phase API e.g., oxycodone HC1 or hydrocodone bitartrate
• PEGs with average molecular weights greater than about 1500 Daltons are ideal for liquid filled capsules because they are thermoplastics that melt at temperatures below the melting point of the hard gelatin capsule ( ⁇ 70 °C ) and are solids at room temperature. If the filling material is liquid at room temperature, a banding process can be used. This process adds a gelatin band around the point where the capsule body and cap join to create a unified capsule body to prevent leakage.
• the formulation of the present disclosure can include a band.
• the liquid fill process can begin by dispensing excipients (e.g., PEG and stabilizers/preservatives) and API according to theoretical percent weights of the final capsule fill weight.
• excipients e.g., PEG and stabilizers/preservatives
• API e.g., PEG and stabilizers/preservatives
• API e.g., PEG and stabilizers/preservatives
• API e.g., PEG and stabilizers/preservatives
• the suspension can be pumped through jacketed hoses (to maintain the internal kettle temperature to prevent solidification in the hose) to a hopper on the capsule filling machine.
• An illustration of a capsule filling machine is provided in Figure 1.
• the capsule filling hopper can also be jacketed to heat the suspension to prevent solidification.
• the capsule filling machine can contain a separate hopper which operators fill with hard gelatin capsules.
• the hopper can feed into a rectifying drum which can align all capsules in the same direction. Once aligned, the capsules can sit vertically in a cap disk which can allow for separation of the body and cap via vacuum.
• a positive displacement piston pump can be used to draw the product in from the jacketed hopper and dispense the suspension into the capsule body through a set of changeable nozzles. Fill weight adjustment can be achieved by varying the piston stroke of the pump. These changes can be made throughout the process due to frequent in-process capsule weight checks.
• the capsule body and cap can be joined via pusher pins which raise the capsule body upwards and into the capsule cap, which are held in place above the capsule body by a joining block.
• the pusher pins can then push the unified capsule out of the cap disk and discharge them from the machine.
• the capsules can then be allowed to cool at room temperature on trays and can be each weight checked via a capsule weigh checking machine. Following this, the capsules can then be placed into a final output drum.
• Automatic capsule filling machines can have the ability to produce 500 to 150,000 capsules an hour with a very high degree of accuracy.
• the present disclosure relates to a dosage form as described herein prepared by filling a capsule body with a heated homogenized suspension including an active substance, a first PEG and a second PEG.
• the homogenized suspension including an active substance, a first PEG, and a second PEG melts at a temperature of about 42 °C, 43 °C, 44 °C, 45 °C, 46 °C, 47 °C, 48 °C, 49 °C, 50 °C, 51 °C, 52 °C, 53 °C, 54 °C, 55 °C, 56 °C, 57 °C, 58 °C, 59 °C, 60 °C, 61 °C, 62 °C, 63 °C, 64 °C, 65 °C, 66 °C, 67 °C, 68 °C, 69 °C, 70 °C, 71 °C, 72 °
• the homogenized suspension has a melting temperature between about 53 °C and about 65 °C.
• the homogenized suspension including an active substance, a first PEG and a second PEG melts at temperatures below 77 °C, i.e., the melting point of the hard gelatin capsule.
• the present disclosure relates to a method of treating pain including administering to an individual in need thereof a therapeutically effective amount of a dosage form as described herein.
• the dosage form can be used for the management of moderate to severe pain where the use of an opioid analgesic is appropriate.
• the dosage form can provide rapid onset of analgesia for the treatment of moderate to severe pain.
• the dosage form e.g., a hard gelatin capsule, can be administered orally every 4-6 hours as needed.
• the disclosures of all cited references including publications, patents, and patent applications are expressly incorporated herein by reference in their entirety. Further, when an amount, concentration, or other value or parameter is given as either a range, preferred range, or a list of upper preferable values and lower preferable values, this is to be understood as specifically disclosing all ranges formed from any pair of any upper range limit or preferred value and any lower range limit or preferred value, regardless of whether ranges are separately disclosed.
• a formulation was prepared containing 30 mg APAP and a 50:50 ratio of PEG 3350:1500 g/mol and 0.50% FD&C dye in size 3 white opaque capsules.
• Three capsule fill weights were evaluated: 100 mg, 150 mg, and 200 mg. These formulations were tested for dissolution.
• Table 1 below list the dissociation data of size 3 capsules containing 30 mg APAP, a 50:50 ratio of PEG 3350:1500 g/mol, and 0.5% FD&C dye.
• These dosage forms contain water- and ethanol-soluble FD&C dyes, e.g., 0.5% FD&C dye, to deter extraction of the API and intravenous injection of the solution. Further rendering of the drug solution would be required to separate the pure API from the PEG and FD&C dyes.
• PEG 1450 (NF grade available from Dow Chemical Company) can be used in place of PEG 1500 in the oxycodone HC1 dosage forms. Additional exemplary oxycodone HC1 dosage forms are shown in Table 2 below. 1 % citric acid may be used in the dosage forms as an API stabilizer.
• ADF oxycodone HC1 liquid fill capsule formulations containing varying amounts of PEG 1450 and PEG 35000 were evaluated.
• Acetaminophen (APAP) was used as a tracer drug for oxycodone HC1.
• the formulations are shown in Table 3 below.
• the target amount of APAP was 30 mg per capsule, and the target fill weight was 100 mg (batch number 92) or 200 mg (batch numbers 93-94).
• the capsules contained 30% w/w (batch number 92) or 15% w/w (batch numbers 93-94) APAP. Size 3 opaque hard gelatin capsules were used.
• a formulation is considered to deter intranasal abuse if ⁇ 75% of the particles are ⁇ 500 ⁇ m in diameter after grinding. As shown in Table 3, the percentage of particles ⁇ 500 ⁇ m in diameter after grinding ranged from 90% to 92%. Thus all of the oxycodone formulations met the standard of ⁇ 75% of the particles being ⁇ 500 ⁇ m in diameter after grinding.
• the oxycodone HC1 formulations were also analyzed to determine melting temperature.
• the capsules were held at 40 °C / 75% relative humidity for 72 hours.
• the batch number 92 and 93 formulations containing 100% and 82% PEG 35000, respectively, were solid at these conditions, while the batch number 94 formulation containing 59% PEG 35000 had a much softer fill.
• hot melt fill capsules are sufficiently viscous at elevated temperatures to allow for flow of the fill into the capsules.
• additional oxycodone HC1 formulations containing PEG 35000 and either PEG 3350 or PEG 1450 were evaluated by measuring viscosity at 75 °C at 50 rpm.
• Formulations were weighed out according to total wt % of a 15g batch. Each formulation was poured into a viscosity testing crucible and placed in an 80 °C water bath to melt.
• the formulations were mixed using a stainless steel spatula and transferred to a Brookfield DV-II+ Pro Viscometer (VIS29 NCD: Upon Use) utilizing Spindle: S27 (Small Sample Adapter).
• the viscometer was equipped with a water jacketed crucible platform. Once the melt temperature reached 75 °C, a viscosity reading was taken in centipoise (cP). Based on manufacturer specifications, an acceptable viscosity for the purposes of this study is ⁇ 1000 cP.
• the particle size after grinding and stability at 40 °C / 75% relative humidity (RH) was also determined. For the grinding analysis, an acceptable particle size after grinding was considered to be ⁇ 75% particles ⁇ 500 ⁇ m in diameter. All
• formulations were size 3 opaque hard gelatin capsules.
• PEG 1450 had a viscosity of 1288 cP at 75 °C / 50 rpm, above the manufacturer specification of ⁇ 1000 cP. Accordingly, viscosity was not measured for the formulations containing higher percentages of PEG 35000 (i.e. batch numbers 97-99). In addition, batch number 100 was not sufficiently stable for storage, since this formulation was a very viscous liquid at the stability test conditions of 40 °C / 75% RH.
• Formulations containing PEG 35000 and PEG 3350 were also evaluated. As shown in Table 6 below, the formulation containing 6.97% PEG 35000 and 62.7% PEG 3350 (batch number 104) and the formulation containing 7.7% PEG 35000 and 69.3% PEG 3350 (batch number 105) met all of the criteria for particle size after grinding, viscosity, and stability.
• Varying concentrations of FD&C Blue #2, green (FD&C Blue #2 and FD&C Yellow #5), FD&C Yellow #5, FD&C Red #40, and grey dye (FD&C Blue#l, FD&C Yellow #6, FD&C Red #40) were evaluated by dissolving them in a 95% ethanol 5% purified water (190 proof) solution and passing the solution through a syringe filter. After syringe filtering the dye solutions were visually evaluated for color intensity and rated on a scale of 0 to 5, with 0 indicating no color and 5 indicating dark, significant color. As shown in the Table 7 below, the blue and green dyes exhibited the highest color intensity at low concentrations, e.g. 0.25% w/w. Solutions of grey dye before and after filtering are shown in Figures 2A and 2B, respectively. The grey dye was particularly striking and less appealing. An acceptable color scale designation after extraction of the dye is ⁇ 4 on a scale of 1 to 5, with 5 being the highest level of color.
• the dye can be grey. Grey can be chosen because it is darker than the others and can be effective at a lower relative concentration. Grey dye can allow for the most visually deterring form with the least amount of dye present in the formulation.
• Abusers of opioid products often adulterate the product to promote more rapid release of the active ingredient.
• the products can be chewed and swallowed, crushed and inhaled, or extracted in water or alcohol (either crushed or intact) to produce a solution that can be used for intravenous administration or dried for insufflation of a purified product.
• Adulteration of the products can enable a more rapid delivery of active than can be achieved by ingestion of the intact product. This rapid onset, high exposure is associated with euphoria, drug liking, and greater abuse potential.
• All C-II narcotic drug products tested can be cut with an edged surface (e.g., scissors or a razor blade) and therefore can potentially be abused, with forces that are substantially lower than what has been reported using the breaking strength test or equivalent (e.g., >500 N). Flattening the tablets using forces greater than 500 N (with traditional "tablet breaking force" definitions) does not address abuse deterrence potential in the tested C-II narcotic drug products.
• the formulation of the present disclosure can be resistant to abuse by nasal insufflation or extraction due to, in part, the waxy nature of the formulation contents and the solubility of the excipients.
• the excipients can be both water and alcohol soluble to create a formulation that makes it time consuming and costly to extract oxycodone HC1 from the formulation contents without also extracting the excipients.
• a high molecular weight PEG can be included because of its solubility properties (e.g., soluble in both alcohol and water) and its resistance to grinding to particle sizes of less than 500 ⁇ m.
• High-molecular weight PEGs are less viscous at melt temperatures than long chain PEO molecules and are soluble in both water and alcohol.
• Dyes can also be used and chosen to be soluble in both water and alcohol to produce a dark colored solution upon extraction and filtering as a visual deterrent to abuse.
• the formulation can include the following components listed in the Table 8 below, including a number of different dyes. Table 8 below lists the components along with their solubility information taken from the various literature sources and tested experimentally (e.g., 200 proof ethanol and filtered through a 0.45 micrometer PTFE filter). The extraction of the active to a pure form can be very difficult using water or alcohol.
• a conventional tablet or powder-filled capsule can be easily crushed to create a fine powder.
• the waxy material contained in the formulations of the present disclosure can make it difficult to manipulate into particles small enough to be easily absorbed by the nasal mucosa.
• the waxy material may also congeal once introduced to the semi-aqueous environment of the nasal passages, which can make it difficult to introduce the oxycodone HC1 or hydrocodone bitartrate to the bloodstream via the nasal passages.
• the formulations of the present disclosure can contain one or more of the following barriers to abuse.
• Insufflation The formulation can be formulated to resist grinding to particle sizes of less than about 500 ⁇ m.
• Extraction and Purification The formulation can be formulated with water- and alcohol-soluble dyes to create a dark colored solution upon extraction that can be visually unappealing to intravenous drug users.
• the water- and alcohol- soluble excipients can present obstacles to purification of the active. In some formulations, if the solvent is flashed off or otherwise evaporated, the excipients can return to the same waxy, dark- colored form as before being introduced to the solvent.
• Vaporization The formulation can contain an active, such as oxycodone HC1, which can degrade at temperatures close to where vaporization occurs. Chewing - Because the formulation is an immediate release formulation, it is not expected that crushing or cutting the dosage form will result in an especially rapid release of the drug to produce a "euphoric high.”
• Table 9 lists exemplary formulations for the oxycodone HC1 abuse deterrent formulation capsules.
• Formulations of the present disclosure were manufactured by the following exemplary process.
• the components of the hot-melt suspension consisting of Polyethylene Glycol 3350, Polyethylene Glycol 35000, Dye Blend, Grey Powder, Citric Acid and Oxycodone HC1 were dispensed according to theoretical batch quantities based on formulation weight percents.
• Polyethylene Glycol 3350, Polyethylene Glycol 35000, Dye Blend, Grey Powder, Oxycodone HC1 and Citric Acid were added to an Olsa 150 Liter Kettle and heated to a temperature of 70 ⁇ 20 °C. Utilizing the homogenizer mixer, external anchor blades and internal mixing blades, the melt was then mixed until uniform
• the formulations of the present disclosure are stable upon storage at 25, 30, 35, 40 or 45 °C, and at 60%, 65%, 70% or 75% relative humidity, e.g., 30 °C / 65% RH or 40 °C / 75% RH.
• the formulation of the present disclosure can be stable under any of these conditions for up to 1 , 2, 3, 4, 5, 6, 9, 12, 16, 18, 24, or 36 months.
• Cutting the dosage form can be performed in order to increase the surface area of the product prior to ingesting it in an effort to increase the rate of dissolution into the digestive tract.
• Cutting can also be used to increase the efficiency of grinding or extraction.
• Grinding the dosage form can be performed in order to decrease the particle size of the product more efficiently than cutting in an effort to insufflate (snort) for immediate release into the blood vessels of the nasal passages.
• a readily available tool used for grinding is a commercially available coffee grinder.
• a drug product is considered abuse deterrent if the % material in the pan ( ⁇ 500 ⁇ m) is ⁇ 50%.
• a dosage form which, when ground, produces ⁇ 50% of the material on a per-dosage form basis available for nasal insufflation ( ⁇ 500 ⁇ m) is considered abuse deterrent.
• Texture analysis is the mechanical testing of pharmaceutical products in order to measure their physical properties.
• the Retsch Knife Mill GRINDOMIX GM200 (TE96) was utilized to mimic a commercially available coffee grinder (Mr. Coffee) in order to grind the drug products into a particle size that is suitable for intranasal abuse (insufflation).
• the Retsch Knife Mill GRINDOMIX GM200 utilizes a circular blade attachment to mimic commercially available coffee grinders.
• the GM200 has a top speed of 10,000 revolutions per minute (rpm), while commercially available coffee grinders have a top speed of approximately 20,000 rpm (an approximate two-fold increase in speed when comparing the GM200 to a Mr. Coffee grinder).
• the approximate two-fold increase in blade diameter (1 18 mm vs. 60 mm, when comparing the GM200 to a Mr. Coffee grinder, respectively) compensates for the approximate twofold decrease in top speed via the inversely proportional relationship of the two variables.
• the torque provided by the GM200 is significantly higher than the torque provided by a Mr.
• Coffee grinder (0.860 Nm (Newton meters) of the GM200 vs. 0.062 Nm of the Mr. Coffee grinder, respectively), which additionally illustrates the ability (or lack thereof) of the Mr. Coffee grinder to modify the drug products into a particle size suitable for intranasal abuse.
• the weight of the 35 mesh sieve and sample pan was recorded.
• the testing apparatus was assembled with the 35 mesh sieve above the sample pan.
• the composite sample was transferred to the testing apparatus and analyzed utilizing the following parameters: 1 minute analysis time and no pulse.
• the analyzed 35 mesh sieve and sample pan were weighed.
• the % material remaining on the 35 mesh sieve ( ⁇ 500 ⁇ m) and in the sample pan ( ⁇ 500 ⁇ m) was calculated using the following equation: x 100
• Table 10 shows the particle size after grinding for the oxycodone HC1 formulations tested. During testing it was observed by visual observation that the capsule portion of the dosage form of all evaluated batches was not being significantly modified by TE96, and that the majority of the capsule portion remained in the 35 mesh sieve ( ⁇ 500 ⁇ m). The grinding / particle size analysis for this protocol is based on weight differences, which, when the capsule portion is taken into account, can skew the results towards a higher proportion of particles ⁇ 500 ⁇ m.
• the average percentage of particles ⁇ 500 ⁇ m after grinding for the oxycodone HC1 capsules ranged from 62.3% to 68.2%.
• approximately 20% of particles by weight of an Immediate Release (IR) Roxicodone® formulation were ⁇ 500 ⁇ m after the same grinding procedure.
• Table 13 summarizes the grinding results and statistical analysis of the % material ⁇ 500 ⁇ m for the Present Disclosure 15mg and Roxicodone® 15mg tablets (Mallinckrodt).
• Another method of rending a drug product abusable is via extraction of the active substance from the dosage form to produce a pure residue.
• This method can be performed, and is often performed, using a high proof alcohol or an aqueous media.
• the formulation of the present disclosure can be readily soluble in both aqueous and alcohol environments when the contents are removed from the capsule. Therefore, aqueous and alcohol extraction techniques were evaluated. Solutions were analyzed qualitatively for solution color following filtration, as well as quantitatively for % label claim (LC) (with regards to oxycodone HCI) of solution following filtration. Additionally, evaporated residual samples were analyzed qualitatively for residue color following evaporation, as well as quantitatively for purity determination following the %LC calculations.
• LC % label claim
• the quantitative results of the analysis determine the % purity (with regards to oxycodone HCI) of the extracted sample solution described above.
• a drug product can be considered abuse deterrent if the % residue purity is ⁇ 50%. In other embodiments, less than or equal to 40%, 45%, 55%, 60%, 65%, 70% or 75%. Residue purity levels (with regards to the API) ⁇ 50% can infer that the excipient load is greater than the API level contained in the residue. In one embodiment, this can be considered abuse deterrent with regards to potential intravenous abuse of a purified residue.
• the F-test and t-tests was analyzed in order to determine if the drug products provide statistically different % purity values.
• Tables 14 and 15 show the formulation of the present disclosure results in 9% and 9% purity with regards to oxycodone HC1, in alcohol and aqueous environments, respectively. This is in comparison to Roxicodone® 15mg, which has a purity of 68% and 19% purity in alcohol and aqueous environments, respectively. This data proves the formulation of the present disclosure is statistically different than Roxicodone 18 in both alcohol and aqueous extracts.
• Color is one identifying characteristic of commercial drug products. Color can be applied to the dosage form in two ways: dye or coating.
• High potency alcohol i.e., ⁇ 190 proof (95%)
• Dyes or coatings can potentially be used to alter the physical appearance of the extracted solution of drug product (i.e., turn the resulting solution a noticeable color).
• the inclusion of one or more dyes in a drug formulation is one method to render a formulation abuse deterrent.
• Significant discoloration of an extraction product from a formulation subject to abuse can discourage a potential abuser from using (e.g., injecting or ingesting) the extraction product.

Landscapes

• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Emergency Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Neurosurgery (AREA)
• General Chemical & Material Sciences (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pain & Pain Management (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=55073631

Family Applications (1)

Country Status (8)

Cited By (1)

Families Citing this family (1)

Citations (7)

Family Cites Families (689)